Jul 1, 2026 09:32AM

Apr 8, 2026 07:31AM

Apr 8, 2026 07:30AM

Mar 30, 2026 07:05AM

Mar 30, 2026 07:03AM

Apr 28, 2025 08:00AM

Apr 24, 2025 08:01AM Northstrive Biosciences (ELAB) Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 with GLP-1 Receptor Agonist for Obesity Treatment

Apr 24, 2025 08:00AM

Mar 10, 2025 08:01AM

Mar 10, 2025 08:00AM

Feb 18, 2025 07:00AM

Feb 4, 2025 08:00AM

Dec 9, 2024 08:03AM

Dec 9, 2024 08:00AM Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation

Oct 22, 2024 09:55AM

Oct 22, 2024 09:54AM

324,704 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All